Utilizing synchronous care to improve cardiovascular and renal health among patients with type 2 diabetes: Proof-of-concept results from the DECIDE-CV clinical programme
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Synchronized cardiometabolic clinics improve guideline-directed medical therapy (GDMT) use for type 2 diabetes patients. This coordinated care significantly reduced key cardiovascular and kidney biomarkers.
Area Of Science
- Cardiology
- Nephrology
- Endocrinology
- Metabolic Diseases
Background
- Type 2 diabetes management is often asynchronous, leading to delayed care and suboptimal use of guideline-directed medical therapy (GDMT).
- Patients with type 2 diabetes frequently have co-existing cardiovascular disease (CVD) or chronic kidney disease (CKD).
Purpose Of The Study
- To evaluate the impact of a synchronized, multidisciplinary outpatient clinic on GDMT utilization and surrogate laboratory biomarkers in patients with type 2 diabetes and high CVD/CKD risk.
- To assess the effectiveness of simultaneous assessment by endocrinology, cardiology, and nephrology.
Main Methods
- Retrospective analysis of 232 patients with type 2 diabetes and CVD or CKD treated in a synchronized DECIDE-CV clinic.
- Assessed changes in GDMT use (SGLT2 inhibitors, GLP-1 RAs, RAS blockers, MRAs) before and after clinic visits.
- Monitored changes in laboratory biomarkers including HbA1c, albumin-to-creatinine ratio, and NT-proBNP.
Main Results
- Significant increases in GDMT use: SGLT2 inhibitors (44% to 87%), GLP-1 RAs (8% to 45%), RAS blockers (77% to 91%), and MRAs (25% to 45%).
- All increases in GDMT were statistically significant (p < .01).
- Significant reductions observed in HbA1c, urinary albumin-to-creatinine ratio, and NT-proBNP levels (p < .05).
Conclusions
- Joint, synchronized assessment in a cardiometabolic clinic effectively enhances the use of GDMT for high-risk diabetes patients.
- This integrated care model leads to significant improvements in surrogate cardiovascular and renal biomarkers.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...